Baker Bros. Advisors Adds $9M in Alumis Inc. ($ALMS)
Key Points
- Baker Bros. Advisors changed its Alumis Inc. ($ALMS) stake by 28.8% last quarter, boosting to 2,012,500 shares worth $42.32 million.
- $ALMS last traded around $21.03.
Baker Bros. Advisors increased its position in Alumis Inc. ($ALMS) by 28.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,012,500 shares of Alumis Inc. after buying 450,000 shares during the quarter. Baker Bros. Advisors's holdings in Alumis Inc. were worth $42.32 million as of its most recent filing.
Alumis Inc. ($ALMS) Stock
Alumis Inc. Earnings
Analysts Set New Price Targets
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.